Earnings summaries and quarterly performance for Enovis.
Executive leadership at Enovis.
Board of directors at Enovis.
Research analysts who have asked questions during Enovis earnings calls.
CC
Caitlin Cronin
Canaccord Genuity
6 questions for ENOV
Also covers: ATEC, AXGN, BVS +12 more
Vijay Kumar
Evercore ISI
6 questions for ENOV
Also covers: A, ABT, AVTR +23 more
DA
Danielle Antalffy
UBS Group AG
5 questions for ENOV
Also covers: ABT, ATRC, BAX +15 more
Joseph Conway
Needham & Company, LLC
3 questions for ENOV
Also covers: AORT, ATRC, HOLX +6 more
RM
Robert Marcus
JPMorgan Chase & Co.
3 questions for ENOV
Also covers: ABT, BAX, BDX +21 more
VC
Vik Chopra
Wells Fargo & Company
3 questions for ENOV
Also covers: ALGN, ATEC, CNMD +8 more
VC
Vikramjeet Chopra
Wells Fargo & Company
3 questions for ENOV
Also covers: ALGN, ATEC, CNMD +9 more
YL
Young Li
Jefferies
3 questions for ENOV
Also covers: ALC, ARAY, ATEC +8 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
2 questions for ENOV
Also covers: ALGN, CBLL, CVRX +17 more
DR
Dane Reinhardt
Robert W. Baird & Co.
2 questions for ENOV
Also covers: INMD
Jeff Johnson
Robert W. Baird & Co.
2 questions for ENOV
Also covers: ALC, ALGN, BBNX +8 more
Jeffrey Johnson
Robert W. Baird & Co. Inc.
2 questions for ENOV
Also covers: ALC, ALGN, BBNX +11 more
KH
Keith Hinton
Freedom Capital Markets
2 questions for ENOV
Also covers: GMED, VCYT, WGS
Michael Matson
Needham & Company
2 questions for ENOV
Also covers: AORT, ATRC, CNMD +22 more
RM
Robbie Marcus
JPMorgan Chase & Co.
2 questions for ENOV
Also covers: ABT, BAX, BDX +15 more
Russell Yuen
William Blair & Company
2 questions for ENOV
Also covers: ALGN, NVST, TRUP
DA
Danielle Antalffy
UBS
1 question for ENOV
Also covers: ATRC, BAX, BBNX +11 more
JW
Jason Wittes
Roth Capital Partners, LLC
1 question for ENOV
Also covers: ALUR, ARAY, ATEC +13 more
Mike Matson
Needham & Company, LLC
1 question for ENOV
Also covers: AORT, ATRC, CNMD +19 more
Recent press releases and 8-K filings for ENOV.
Enovis Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
ENOV
Earnings
Guidance Update
Product Launch
- Enovis reported full year 2025 sales of $2.2 billion, a 7% reported increase and 6% organic growth, with Q4 sales at $576 million (3% reported, 2% organic).
- For the full year 2025, the company achieved an adjusted EBITDA margin of 17.9% and adjusted earnings per share of $3.30, up 16%.
- The company returned to positive free cash flow of $20 million in 2025, representing 10% conversion, and reduced leverage to 3.1 times.
- Enovis provided 2026 revenue guidance of $2.31 billion-$2.37 billion, expecting 4%-6% organic growth and adjusted EBITDA of $425 million-$435 million.
- The company forecasts 25% plus free cash flow conversion in 2026 and prioritizes debt reduction in its capital allocation strategy.
1 day ago
Enovis Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
ENOV
Earnings
Guidance Update
New Projects/Investments
- Enovis reported Q4 2025 net sales of $576 million and Adjusted EPS of $0.95, contributing to full-year 2025 net sales of $2,248 million and Adjusted EPS of $3.30.
- For the full year 2025, the company achieved +7% reported sales growth and +6% organic sales growth, with the Reconstructive segment showing +7% Y/Y growth and +3% organic growth in Q4.
- Enovis demonstrated improved financial discipline, exceeding 10% Free Cash Conversion and reducing its Net Leverage Ratio to 3.1X by the end of 2025.
- The company issued a Full Year 2026 outlook, forecasting revenue between $2.31 billion and $2.37 billion, Adjusted EPS of $3.52-$3.73, and Free Cash Conversion of 25%+.
1 day ago
Enovis Reports Q4 and Full Year 2025 Results, Issues 2026 Guidance
ENOV
Earnings
Guidance Update
Product Launch
- Enovis reported Q4 2025 sales of $576 million, up 3% reported and 2% organically, contributing to full-year 2025 sales of $2.2 billion with 6% organic growth. For the full year, adjusted EBITDA margin was 17.9% and adjusted EPS reached $3.30.
- The Recon segment achieved 8% organic growth and the Prevention and Recovery (PNR) segment accelerated to 4% organic growth in 2025. The company returned to positive free cash flow of $20 million for the year, representing 10% free cash flow conversion.
- For 2026, Enovis expects revenues between $2.31 billion and $2.37 billion, with 4%-6% organic revenue growth. Adjusted EBITDA is projected to be $425 million-$435 million (a 50 basis point margin improvement), and adjusted EPS is forecast at $3.52-$3.73.
- The company aims for free cash flow conversion of 25% plus of adjusted net income in 2026 and emphasizes debt reduction as its primary capital allocation priority. They also plan to ramp up the enhanced ARVIS product throughout 2026.
1 day ago
Enovis Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
ENOV
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Enovis reported full year 2025 sales of $2.2 billion, up 7% reported and 6% organically, with adjusted EPS increasing 16% to $3.30. The company also returned to positive free cash flow of $20 million.
- For 2026, Enovis forecasts revenues between $2.31 billion and $2.37 billion, driven by 4%-6% organic growth, and expects adjusted EBITDA of $425 million-$435 million. Adjusted EPS is projected to be $3.52-$3.73, with free cash flow conversion exceeding 25%.
- In 2025, the company achieved 8% organic growth in Recon and 4% organic growth in Prevention and Recovery (PNR), while maintaining adjusted EBITDA margins at 17.9%.
- A non-cash technical goodwill impairment of $501 million was recorded in Q4 2025, which does not affect Enovis' liquidity, cash flows, debt covenants, or future operations.
1 day ago
Enovis Announces Fourth Quarter and Full Year 2025 Results and 2026 Outlook
ENOV
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Enovis reported full-year 2025 net sales of $2.2 billion, an increase of 7% on a reported basis and 6% organically, with adjusted diluted earnings per share of $3.30 and adjusted EBITDA of $403 million.
- For the full year 2025, Reconstructive sales grew 10% on a reported basis and 8% organically, while Prevention & Recovery sales increased 4% on both reported and organic bases.
- In the fourth quarter of 2025, net sales were $576 million, growing 3% on a reported basis and 2% organically, with adjusted diluted earnings per share of $0.95.
- The company recorded a non-cash goodwill impairment charge of $1,050 million for the full year 2025, contributing to a net loss from continuing operations of $1,182 million.
- For 2026, Enovis projects revenue between $2.31-2.37 billion (4-6% organic growth), adjusted EBITDA of $425-435 million, and adjusted earnings per share between $3.52 to $3.73.
1 day ago
Enovis Announces Q4 and Full Year 2025 Results and 2026 Outlook
ENOV
Earnings
Guidance Update
- Enovis reported full year 2025 net sales of $2.2 billion, an increase of 7% on a reported basis and 6% organically, with adjusted diluted earnings per share of $3.30.
- For the fourth quarter of 2025, net sales were $576 million, up 3% on a reported basis and 2% organically, and adjusted earnings per diluted share were $0.95.
- The company recorded a significant non-cash goodwill impairment charge of $501 million in Q4 2025, contributing to a full year net loss from continuing operations of $1,182 million.
- Enovis provided a 2026 financial outlook, expecting revenue between $2.31 billion and $2.37 billion, adjusted EBITDA in the range of $425 million to $435 million, and adjusted earnings per share from $3.52 to $3.73.
1 day ago
Enovis Announces Fourth Quarter and Full Year 2025 Results and 2026 Outlook
ENOV
Earnings
Guidance Update
- Enovis reported full year 2025 net sales of $2.2 billion, reflecting 7% reported growth and 6% organic growth.
- For the fourth quarter of 2025, net sales were $576 million, growing 3% on a reported basis and 2% organically compared to the same quarter in 2024.
- The company incurred a full year 2025 net loss from continuing operations of $1,182 million and a fourth-quarter net loss of $519 million, both primarily due to non-cash goodwill impairment charges.
- Adjusted diluted earnings per share for full year 2025 was $3.30, and for the fourth quarter of 2025 was $0.95.
- For 2026, Enovis expects revenue to approximate $2.31-2.37 billion (4-6% organic growth) and adjusted earnings per share to be in the range of $3.52 to $3.73.
1 day ago
Enovis Updates 2025 Guidance and Strategic Outlook
ENOV
Guidance Update
M&A
Revenue Acceleration/Inflection
- Enovis updated its 2025 guidance as of January 12, 2026, projecting reported revenue of $2.24-2.25 billion, adjusted EBITDA of $400-405 million, and adjusted EPS of $3.25-$3.35.
- The company is strategically focused on aggressively growing its Reconstructive (Recon) segment, which has sales of approximately $1.1 billion and holds a global leadership position in Shoulder and Dynamic Fusion Solutions, while also shaping its Prevention & Recovery (P&R) segment for higher growth and gross margin.
- Enovis has demonstrated consistent financial execution, with adjusted gross profit margins reaching 59.3% and adjusted EBITDA margins at 17.9% in 2024, and aims for +50 basis points annual margin expansion in its long-range plan.
- The company targets efficient cash generation with a long-range plan goal of +70% free cash flow conversion, supported by a projected decrease in CAPEX as a percentage of sales from 9% in 2024 to ~8% in 2025.
Jan 13, 2026, 12:30 AM
Enovis Updates on Financial Performance, Strategic Focus, and Product Launches at J.P. Morgan Conference
ENOV
Guidance Update
Product Launch
M&A
- Enovis reported approximately $2 billion in revenue with 6% core growth and 12% growth including M&A. The company raised its 2025 EBITDA and EPS guidance despite a slight top-line miss, attributing the profit beat to improved gross margins and cost management.
- For 2026, Enovis projects mid-single digit organic growth and greater than 25% free cash flow conversion, with a long-term target of 70%+ free cash flow conversion. The company also aims for 50 basis points plus annual margin expansion, primarily through gross margin improvements and reduced SG&A.
- The company is pausing M&A to prioritize commercial execution, operational excellence, and financial discipline, with a goal to reduce debt leverage from 3.2x at the end of 2025 to below 3x before pursuing further acquisitions.
- Enovis is set to fully launch ARVIS 2.0 in March, a user-friendly and cost-effective robotic system for knee and shoulder procedures, which is expected to indirectly boost implant sales.
Jan 13, 2026, 12:30 AM
Enovis Provides Business Update and Financial Outlook at J.P. Morgan Healthcare Conference
ENOV
Guidance Update
Revenue Acceleration/Inflection
M&A
- Enovis, an orthopedics company with approximately $2 billion in revenue and 6% core growth, recently raised its guidance on EBITDA and EPS.
- The company has improved margins from 14% to 18% and aims for 20%, with a strategic focus on commercial execution, innovation, and financial discipline following 20+ acquisitions.
- For 2026, Enovis is guiding towards mid-single-digit organic growth and expects greater than 25% free cash flow conversion, working towards a long-term goal of 70%+.
- The company is currently at 3.2x leverage at the end of 2025 and aims to reduce it below 3x before considering further M&A, having paused acquisitions to focus on integration and organic growth.
- The ARVIS 2.0 navigation system, designed to support implant sales, will have its "coming out party" in March, with an initial focus on shoulder procedures.
Jan 13, 2026, 12:30 AM
Quarterly earnings call transcripts for Enovis.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more